Viewing Study NCT06462469

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:05 PM
Ignite Modification Date: 2026-01-12 @ 11:30 PM
Study NCT ID: NCT06462469
Status: RECRUITING
Last Update Posted: 2025-11-25
First Post: 2024-06-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Steroid-refractory Acute Graft Versus Host Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None SR-aGvHD View
None aGvHD View
None acute graft-versus-host disease View
None ruxolitinib View
None Chinese patients View
None corticosteroid-refractory View
None Grade II-IV View
None Grade II to IV View